Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity

Area of Science:

• Pharmacology
• Oncology
• Epidemiology

Background:

• The International Agency for Research on Cancer (IARC) classifies many substances, including pharmaceuticals, as potentially carcinogenic based on animal or limited human data.
• Evaluating the carcinogenic potential of pharmaceuticals in human populations is crucial for patient safety and drug regulation.

Purpose of the Study:

• To assess the evidence of carcinogenicity for nine pharmaceuticals previously flagged by the IARC.
• To investigate potential associations between specific drug exposures and cancer development in a large patient cohort.

Main Methods:

• Nested case-control analyses were conducted within a cohort of 6.5 million individuals with up to 12 years of follow-up.
• Automated pharmacy records and a cancer registry were utilized to link drug exposure with cancer incidence.
• Analyses focused on specific cancer sites and included dose-response assessments and sensitivity analyses for confounding factors.

Main Results:

• Supportive evidence for carcinogenicity was found for griseofulvin, metronidazole, and phenytoin.
• Cyclophosphamide, a known carcinogen, was included for validation and its results supported the study's methodology.
• Associations for oxazepam and propylthiouracil were potentially explained by confounding factors like smoking and thyroid disease.

Conclusions:

• The study provides supportive evidence for the carcinogenicity of griseofulvin, metronidazole, and phenytoin.
• Findings for other evaluated pharmaceuticals were largely non-contributory or potentially confounded.
• These results warrant consideration in the ongoing evaluation and risk assessment of these pharmaceutical agents.